taletrectinib + famotidine

Taletrectinib + famotidine is a drug combination used in clinical pharmacology studies to evaluate the impact of gastric acid reduction on the pharmacokinetics of taletrectinib. Taletrectinib (brand name IBTROZI) is a highly selective, CNS-active, next-generation oral tyrosine kinase inhibitor (TKI) targeting ROS1 and NTRK fusion proteins, primarily developed for ROS1-positive non-small cell lung cancer (NSCLC). Famotidine is a histamine H2-receptor antagonist that reduces stomach acid production. In this context, famotidine serves as a pharmacokinetic probe to determine if taletrectinib's absorption is pH-dependent, which informs clinical dosing recommendations regarding the co-administration of acid-reducing agents like H2 blockers or proton pump inhibitors.